Christopoulos P, Bozorgmehr F, Bruckner L, Chung I, et al. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. BMC Cancer 2021;21:743.
PMID: 34182952